GSK Gets CDSCO Panel Nod to study safety of anti-cancer drug Dostarlimab

GSK has received approval from the Central Drugs Standard Control Organization (CDSCO) panel to conduct a study on the safety of their anti-cancer drug, Dostarlimab. The study will focus on assessing the safety of the drug and its potential side effects. This approval allows GSK to proceed with conducting the study in India. The company aims to gather more data on the safety and effectiveness of Dostarlimab in treating cancer. GSK’s efforts in conducting this study align with their commitment to developing and providing safe and effective treatments for cancer patients.

Source link